鲁索利替尼在骨髓纤维化中的应用

IF 4.3 Q1 Medicine

Biology of Blood and Marrow Transplantation Pub Date : 2020-12-01 DOI:10.1016/j.bbmt.2020.08.015

Uroosa Ibrahim, Giulia Eva Maria Petrone, John Mascarenhas, Alla Keyzner

{"title":"鲁索利替尼在骨髓纤维化中的应用","authors":"Uroosa Ibrahim, Giulia Eva Maria Petrone, John Mascarenhas, Alla Keyzner","doi":"10.1016/j.bbmt.2020.08.015","DOIUrl":null,"url":null,"abstract":"<div><p>Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.015","citationCount":"1","resultStr":"{\"title\":\"Peritransplantation Use of Ruxolitinib in Myelofibrosis\",\"authors\":\"Uroosa Ibrahim, Giulia Eva Maria Petrone, John Mascarenhas, Alla Keyzner\",\"doi\":\"10.1016/j.bbmt.2020.08.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.</p></div>\",\"PeriodicalId\":9165,\"journal\":{\"name\":\"Biology of Blood and Marrow Transplantation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.015\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biology of Blood and Marrow Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1083879120305073\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology of Blood and Marrow Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1083879120305073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

Ruxolitinib是一种口服JAK1/2抑制剂，被批准用于中高风险骨髓纤维化(MF)患者，基于其已证实的脾脏和症状负担减轻。然而，它对造血干细胞移植(HSCT)结果的影响在很大程度上是未知的。大量进行HSCT的患者已经接受了ruxolitinib治疗，在已发表的文献中，ruxolitinib在移植周围使用的具体情况差异很大。在这里，我们回顾了目前发表的数据和经验，以指导MF患者在鲁索利替尼治疗下进行HSCT的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Peritransplantation Use of Ruxolitinib in Myelofibrosis

Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biology of Blood and Marrow Transplantation 医学-免疫学

CiteScore

6.60

自引率

0.00%

发文量

1061

审稿时长

3-6 weeks

期刊介绍： Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.